Gland Pharma listed in November 2020 and has risen over 50 percent from its issue price of Rs 1500 per share. The stock trades at over 30 times its FY22 price to earnings.
“The growth is strong, our orderbook is strong for the next year and we have several strong launches as well. We, being a B2B business model, know how our numbers look like for the year,” said Srinivas Sadu, MD & CEO of Gland Pharma in an interview with CNBC-TV18 on Wednesday.
The year 2020 was different due to COVID-19, said Sadu.
“We have proved that our company is resilient to changes in the market.”
On the growth front, he said, “We have mergers and acquisitions (M&A) in mind but that has to fit in our growth strategy as well.”
He said Gland Pharma is strong in anti-infective and get around 30 percent of revenue from the segment.
Watch the video for more